California Retina Consultants: Company Profile

Background

Overview

Established in 1969, California Retina Consultants (CRC) was the first to provide vitreoretinal care to patients on the Central Coast of California. Over the decades, CRC has expanded to become one of the largest and most respected retina groups globally, operating 12 specialized centers across Central and Southern California. The practice is dedicated to the diagnosis, prevention, and treatment of retinal, macular, and vitreous disorders, emphasizing conditions such as age-related macular degeneration (AMD), diabetic retinopathy, and retinal vascular occlusions.

Mission and Vision

CRC's mission is to provide the highest quality retinal care with low complication outcomes, ensuring that treatments are delivered in a personal, ethical, and caring manner. The vision is to advance global standards of care through research and clinical trials, thereby reducing the number of individuals suffering from blindness and vision loss.

Industry Significance

As a pioneer in vitreoretinal care, CRC has significantly influenced the field by introducing advanced diagnostic and treatment modalities. Its commitment to research and education has positioned it as a leader in retinal care, contributing to improved patient outcomes and the advancement of retinal medicine.

Key Strategic Focus

Core Objectives

Comprehensive Care: Offer a full spectrum of medical and surgical treatments for retinal, macular, and vitreous conditions.

Research and Education: Engage in cutting-edge clinical trials and educational initiatives to advance retinal care.

Patient-Centered Approach: Maintain a compassionate and ethical environment for patients, ensuring personalized care.

Areas of Specialization

Age-Related Macular Degeneration (AMD): Both dry and wet forms.

Diabetic Retinopathy: Management and treatment.

Retinal Vascular Occlusions: Diagnosis and intervention.

Retinal Tears and Detachments: Surgical repair and management.

Macular Conditions: Including macular holes and macular pucker.

Key Technologies Utilized

Advanced Imaging: State-of-the-art ophthalmic imaging capabilities for accurate diagnostics.

Intravitreal Injections: Utilization of anti-VEGF therapies such as Avastin, Eylea, Lucentis, and Vabysmo.

Surgical Techniques: Pioneering small-gauge surgery and Susvimo implant surgery.

Primary Markets Targeted

CRC primarily serves patients across Central and Southern California, with a focus on communities in Santa Barbara, Santa Maria, Valencia, Lompoc, and surrounding areas.

Financials and Funding

Funding History

As a privately held entity, CRC has not publicly disclosed detailed financial information or funding history. The practice's growth and expansion are supported through revenue generated from patient services and strategic partnerships.

Recent Developments

In 2020, CRC became part of Retina Consultants of America (RCA), a network of leading retinal care and research practices in the United States. This partnership aims to enhance CRC's capabilities in providing state-of-the-art treatment options and advancing retinal care.

Pipeline Development

Clinical Trials and Research

CRC operates the California Retina Research Foundation (CRRF), established in 2001, which has enrolled over 1,000 patients in more than 50 clinical trials. These trials focus on experimental retinal treatments, including retinal gene therapy, and aim to advance the understanding and management of retinal diseases.

Notable Pipeline Candidates

Retinal Gene Therapy: Investigating gene-based treatments for retinal degenerative diseases.

Anti-VEGF Therapies: Ongoing studies to evaluate the efficacy of various anti-VEGF agents in treating AMD and diabetic retinopathy.

Anticipated Milestones

While specific timelines for these clinical trials are not publicly disclosed, CRC's active participation in national and international research initiatives positions it to contribute significantly to the advancement of retinal care in the near future.

Technological Platform and Innovation

Proprietary Technologies

CRC has pioneered the use of small-gauge surgery in the Western United States, enhancing surgical precision and patient recovery times.

Significant Scientific Methods

Clinical Trials: Leading and participating in national and international clinical trials to evaluate new treatments for retinal diseases.

Educational Initiatives: Conducting annual educational meetings and publishing scientific papers to disseminate knowledge and foster innovation in retinal care.

AI-Driven Capabilities

While specific AI-driven technologies are not detailed, CRC's commitment to advanced diagnostics and treatment suggests the integration of cutting-edge technologies to enhance patient care.

Leadership Team

Key Executives

Dr. Robert Avery, M.D.: Retina Specialist.

Dr. Ma’an Nasir, M.D.: Retina Specialist.

Dr. Dante Pieramici, M.D., FASRS: Retina Specialist.

Dr. Alessandro Castellarin, M.D.: Retina Specialist.

Dr. Stephen Couvillion, M.D.: Retina Specialist.

Dr. Nathan Steinle, M.D.: Retina Specialist.

Dr. Dilsher Dhoot, M.D., FASRS: Retina Specialist.

Dr. Daniel Learned, M.D.: Retina Specialist.

Dr. Dong Yang, M.D.: Retina Specialist.

Dr. Andrew Clark, M.D., PhD: Retina Specialist.

Dr. Ankur Gupta, M.D., M.S.: Retina Specialist.

Professional Backgrounds

Each physician at CRC is board-certified or board-eligible in ophthalmology, having completed extensive fellowship training in medical and surgical vitreoretinal diseases at prestigious medical centers and universities, including Harvard University and Johns Hopkins.

Key Contributions

Clinical Excellence: Providing high-quality medical care and treatment for retinal diseases.

Research Leadership: Leading and participating in groundbreaking national and international clinical trials.

Educational Impact: Contributing to leading academic publications and conducting annual educational meetings.

Leadership Changes

In February 2026, Dr. Ma’an Nasir retired after 30 years of dedicated service, leaving a legacy of leadership in clinical care, research, and innovation in retinal medicine.

Market Insights and Competitor Profile

Market Dynamics

The retinal care market in California is characterized by a growing demand for specialized services driven by an aging population and increasing prevalence of retinal diseases. This demand fosters competition among established practices and emerging providers.

Competitor Analysis

Retina Consultants of Southern California: Founded in 2000, operating in Redlands, Riverside, and Victorville, it focuses on retinal medicine and surgery.

Retina Macula Consultants of California: Based in Pasadena, specializing in retinal care with an emphasis on macular conditions.

Strategic Collaborations and Partnerships

The 2020 partnership between CRC and Retina Consultants of America (RCA) extends CRC's capabilities, offering access to advanced treatment options, collaborative research, and a broader patient population.

Operational Insights

CRC's network of 12 locations across Central and Southern California enhances patient accessibility and market reach. Its dedication to research and education differentiates it from competitors.

Strategic Opportunities

CRC is positioned to expand its research programs, especially in retinal gene therapy, and advance service offerings through innovations and partnership synergies within RCA.